insights_auto
Miks on 4142 langenud? 6,62%?
Uurige põhjalikumaltchevron_right
4142:TPE
Adimmune Corp
14,80 NT$
arrow_downward
−6,62%(−1,05) 1 p
20. nov, 13:30:09 GMT +8 · TWD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4142 põhistatistika genereerimine…
Ava
15,75 NT$
Kõrge
15,75 NT$
Madal
14,80 NT$
Turu kapit.
6,36 mld
Keskm. maht
1,13 mln
Maht
1,63 mln
Hinna ja tulu suhe
85,76
52 näd kõrgeim
21,50 NT$
52 näd madalaim
14,80 NT$
Aktsiatulu
0,17 NT$
Käibivad aktsiad
235,29 mln
Töötajate arv
564
Ava
15,75 NT$
Kõrge
15,75 NT$
Madal
14,80 NT$
Turu kapit.
6,36 mld
Keskm. maht
1,13 mln
Maht
1,63 mln
Hinna ja tulu suhe
85,76
52 näd kõrgeim
21,50 NT$
52 näd madalaim
14,80 NT$
Aktsiatulu
0,17 NT$
Käibivad aktsiad
235,29 mln
Töötajate arv
564
Uudised
Veebiallikatest ja uudistepartneritelt
AP News
·
12 tunni eest
S&P 500 sinks 3.7% and Nasdaq composite goes negative for the year as tech sell-off worsens
Trefis
·
2 tunni eest
25 S&P 500 Stocks Just Made New 52-Week Lows
Yahoo Finance
·
14 tunni eest
Wall St ends sharply lower on AI selloff, S&P 500, Dow in correction
ABC News - Breaking News, Latest News and Videos
·
1 päeva eest
S&P 500 sinks 3.7% and the Nasdaq composite goes negative for the year as rout in tech stocks tanks the market
Profiil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Teave üksuse Adimmune Corp kohta